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Microbiology Resources in Developing Countries
In industrialized countries, it is the best of times for the
microbiologic diagnosis and treatment of infections. In some
developing countries, progress is also apparent. Ministries of
health are building hospital intensive care units (ICUs), with
sophisticated medical devices, procedures, and interventions.
Increasing numbers of infants and adults are being admitted
to, and benefiting from, these units. More patients with
conditions such as chronic renal failure or hematologic
disorders are being treated in specialized units. The Internet
has made physicians generally more knowledgeable than
before.
Nevertheless, it is the worst of times for hospitals in other
developing countries, where infectious diseases remain the
leading cause of death (1). Many sentinel hospitals have less
than basic microbiology laboratory facilities; there is no end
in sight to the HIV epidemic, and the prevalence rate of
tuberculosis (TB) is increasing in parallel with it; hospital
infections, especially surgical site infections, have become
important causes of illness and death in certain hospitals in
sub-Saharan Africa (unpublished data); and invasive medical
devices and procedures are increasingly being introduced into
ICUs and operating theaters without the necessary infection
control procedures. In some developing countries, some
institutions have all the needed microbiologic resources,
while others have none; some hospital laboratories have
instruments and reagents yet have no technical staff to use
them; others may be able to amplify genomes yet cannot
report the results of a simple Gram stain in a timely manner.
For all these reasons, the causes of many infections among
inpatients in Africa, Southeast Asia, the Indian subcontinent,
and parts of the Americas remain largely unknown or
uncharacterized.
In sub-Saharan Africa and Southeast Asia, antimicro-
bial-drug resistance is being increasingly recognized in
pathogens that commonly cause infections in health-care
settings, rendering available antimicrobial agents ineffective
and further shortening the list of already scarce effective
agents (2). Thus, to diagnose and treat infections
appropriately and to fully characterize emerging infections in
developing countries, enhanced clinical microbiology services
are a priority. The clinical microbiology laboratory in
developing countries should be patient directed and guided by
clinical reality and not by high technology or outside
interests.
Two other factors have had a marked effect on the role of
clinical microbiology in developing countries, the HIV and TB
epidemics. Most (95% of the global total) people with HIV
infection live in the developing world (3,4). In almost 6 million
of the 34 million adults and children with HIV or AIDS, HIV
infection was diagnosed during 1999 (4); 3.8 million cases
occurred in sub-Saharan Africa and 1.3 million in South and
Southeast Asia. Of the approximately 40 million TB cases
globally, 73% are projected to have occurred in Southeast Asia
and sub-Saharan Africa (5). TB, which accounts for almost
one third of the AIDS deaths worldwide, and other
opportunistic bacterial, fungal, and protozoal infections are
leading causes of death among HIV-infected patients (3-5).
Thus, HIV infection, TB, and HIV-related opportunistic
infections have overwhelmed existing resources in hospital
microbiology laboratories in most developing nations.
At the Centers for Disease Control and Prevention (CDC),
a main objective of the strategy for preventing and controlling
emerging infectious diseases in developing countries is
establishing more effective international surveillance
networks (6). In the industrialized world, infection control
relies on results from individual patient-directed diagnostic
microbiology laboratory tests. However, basic clinical
microbiology has not been recognized as a priority by donor or
governmental agencies in industrialized countries or by the
developing countries themselves. The problem often has been
compounded by lack of trained laboratory personnel or
prohibitive costs associated with maintaining a laboratory.
Where resources are available, they may be used
inappropriately (e.g., nonessential stool, urine, or sputum
cultures; antimicrobial susceptibility testing of microorgan-
isms without quality assurance; or complete laboratory
characterization and antimicrobial susceptibility testing of
bacterial isolates that are not clinically relevant).
Prohibitive costs and doubtful cost-effectiveness of
specific tests are commonly cited as reasons for the
unavailability of microbiology tests. The first steps in
achieving cost-effective use of resources include assessing
whether or not a test has sufficient diagnostic value to be used
and establishing criteria to limit processing to those
organisms most likely to be clinically relevant (7). The concept
of clinical value encompasses several issues (8): Why was the
test requested? Will the result help or alter patient
management? Would a simpler test do? Will the use of a test
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increase knowledge? Can we do without it? Is the test of public
health or clinical importance? For example, hospitals in
developing countries still routinely obtain and process
anaerobic blood cultures, despite that a positive anaerobic
blood culture often reflects an underlying anaerobic infection
(e.g., intraabdominal sepsis or female genital tract infection)
that already is clinically apparent or discernible (9,10). The
counter argument is that while such data may reflect reality
for a microbiology issue in industrialized nations, they may
not be applicable for developing settings—all the more reason
for important questions about diagnostic clinical microbiol-
ogy in developing countries to be addressed through evidence-
based clinical studies.
The importance of integrating epidemiology and
microbiology is exemplified by studies that ascertained the
usefulness of expensive HIV confirmation tests in developing
countries. In industrialized countries, confirmation of HIV
serologic tests with the Western blot molecular technique is
standard practice. In developing countries, the Western blot
often is not used because of its complexity and high cost. A
study conducted in Thailand with epidemiologic, clinical, and
microbiologic components has shown that the use of two
enzyme-linked immunosorbent assays (ELISAs) to confirm
the presence of HIV antibodies produces results comparable
with those of the Western blot (11). This approach to
confirming HIV status was used effectively in Tanzania (12),
Thailand (13), and Malawi (14). Thus, in a country with a high
prevalence rate of HIV infection, limited financial resources,
and inadequate laboratory infrastructure, Western blot
analysis for confirmation of HIV infection is neither
mandatory nor necessary.
Medical services in industrialized nations rely on results
from individual, patient-directed, diagnostic microbiology
laboratory tests ordered by clinicians. This system appears
effective for industrialized settings and is generally
sustainable. Not surprisingly, diagnostic microbiology
services in some developing countries have been modeled on
these practices in industrialized countries. However, such
routine laboratory testing may be impossible in developing
settings because of lack of microbiology services, or, where
these services are available, tests may be unreliable if
performed improperly or without adequate quality control.
Further, the tests may well be inappropriate, irrelevant, or
redundant. For example, antimicrobial susceptibility testing
without quality controls may lead to invalid or distorted data
that give rise to bias and inaccuracy in reports being used for
clinical and public health decision making.
Hospital Cohort-Based Studies
During the past few years, the Hospital Infections
Program at CDC and the Clinical Microbiology Laboratory at
Duke University Medical Center participated in hospital
cohort-based microbiologic surveys. These surveys are
conducted with a cohort of patients who meet simple, objective
entry criteria or case definitions (e.g., fever, diarrhea,
cellulitis, or specific syndromes). Detailed clinical and
epidemiologic data are collected for later analyses, and
cultures with a high positive predictive value for infection
(e.g., blood, cerebrospinal fluid, other sterile sites, or stool for
enteric pathogens) are obtained. The emphasis is on
performing quality-controlled laboratory testing for a finite
period rather than long-term, routine diagnostic testing.
These surveys have been conducted in selected hospitals or
laboratories that provide a natural gathering point to sample
patients meeting these entry criteria. A cohort-based study
acting as a surveillance “probe” for a finite period may be more
effective than individual patient-directed laboratory testing
in providing useful clinical and public health information, in
determining the true incidence and prevalence rates of
emerging pathogens and antimicrobial-drug resistance, and
in yielding clinical predictors for various infections in defined
patient cohorts. In addition, cohort-based studies provide the
opportunity to establish diagnostic capability in basic clinical
microbiology in sentinel hospitals or laboratories and
promote surveillance activities in regions where critical
public health infrastructure has been neglected.
Cohort Studies of Bloodstream Infection
To test this approach to clinical microbiology, CDC and
Duke conducted cohort-based studies of bloodstream
infections among inpatients in sub-Saharan Africa and
Southeast Asia (12-15). Fever was chosen as the initial case
definition because it may be attributed to HIV infection,
diarrhea, pneumonia, TB, or, in sub-Saharan Africa, malaria.
Blood cultures were obtained because of their high positive
predictive value for presence of bloodstream infections in
febrile patients.
In Thailand about half of consecutive febrile adults
admitted to a sentinel teaching hospital for infectious
diseases had bloodstream infections (13); in a similar patient
cohort in a Malawi teaching hospital, approximately one
quarter of patients had a bloodstream infection (14). In both
countries,  Mycobacterium tuberculosis,  Streptococcus
pneumoniae, and Salmonella spp. were the predominant
causes of bloodstream infections in these patients. Data from
these studies also included clinical predictors for bloodstream
infections and antimicrobial susceptibility profiles of
clinically important isolates (including M. tuberculosis
isolates). Both the predictors and susceptibility profiles were
potentially useful for developing algorithms for empiric
treatment of febrile inpatients and for helping clinicians
decide which patients would most benefit from limited blood
culture services, where these were available. Through cohort-
based studies in Malawi during the dry and wet seasons, we
demonstrated seasonal variation in bloodstream infection: S.
pneumoniae and M. tuberculosis were the predominant
bloodstream pathogens during the dry season, whereas
Salmonella spp. were the predominant bacteria isolated
during the wet season (16). We also documented that malaria
was overdiagnosed in both the wet and dry seasons in Malawi
and that empiric therapeutic decisions had to reflect these
realities (16).
Cohort-based studies in Thailand and Malawi demon-
strated the occurrence of occult mycobacteremia (15): 42% of
patients with M. tuberculosis bloodstream infections had
neither symptoms nor signs of pulmonary TB. These results
highlighted the importance of maintaining a low threshold of
suspicion for active TB; the need for strengthening each
hospital’s microbiology capabilities to examine and report on
sputum smears for acid-fast bacilli; and the potential for
intrahospital TB transmission from seemingly noninfectious
patients.
The public health implications of the cohort-based
approach are enormous. Conducting similar studies in other
countries would improve microbiology services by encourag-
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laboratories and focusing on clinically relevant problems
(e.g., bloodstream infections, meningitis, pneumonia, febrile
diarrhea, and surgical wounds). Moreover, laboratory
personnel would benefit from training to conduct quality-
controlled tests, such as antimicrobial-drug susceptibility
testing. Prevalence rates of common infections, HIV infection,
or resistance of common hospital pathogens to available
antimicrobial agents would be available for clinical and
public health decision making. Updated lists of probable
diagnoses, clinical predictors for specific infections, and
development of clinical algorithms and antimicrobial-drug
susceptibility profiles based on these objective data would
enhance patient care through rational diagnosis and
prescribing policies.
Although it may not be economically feasible to obtain
cultures for all patients who might benefit from microbiologic
tests in developing countries, cohort-based studies could be
applied to establish the causes and clinical predictors for
these infections and thereby facilitate directed rather than
blind empiric therapy.
Hospital laboratories in developing countries need to
establish screening and rejection criteria for specimens
submitted for culture. Laboratory directors need to address
certain questions: Will the results alter patient management?
What is the public health importance? What is the relative
yield of a Gram-stained smear versus a complete culture?
Data from cohort-based studies in one region or country
are not suitable for direct extrapolation to other regions or
countries. Rather, regional, season-specific surveillance
studies can be tools for optimizing patient care where routine
laboratory testing is not available. The task remains to define
the role of new and emerging pathogens in various patient
populations at hospitals in developing countries.
The Role of Sentinel Hospitals
During the past 5 years, our cohort-based approach to
collaborative global endeavors in health-care epidemiology
has included identifying sentinel hospitals and then
enhancing their  clinical microbiology laboratory capacity by
infection control assessments and interventions. In develop-
ing countries, where limited resources and infrastructure
may preclude comprehensive medical, surgical, and
laboratory services for every region or province, centralization
of available resources in a few selected centers is one way of
optimizing resources. This paradigm is evident in many
countries in Southeast Asia, Africa, Latin America, and the
Caribbean, where a few institutions have evolved into
sentinel centers of paramount importance for providing such
services.
Sentinel hospitals tend to be large institutions (usually
>500 beds) that are the main teaching centers for medicine,
surgery, nursing, and laboratory science; they commonly
house specialized ICUs, surgery, hemodialysis, or invasive
medical procedures; they have problems with hospital
infections and antimicrobial-drug resistance; they are
associated with microbiology laboratories that are often
reference centers with the ability and capacity to conduct
various microbiologic tests using scrupulous, quality-
controlled methods; and they usually are government
affiliated and have very close links with the respective
ministry of health. The last attribute is important since
governmental agencies from industrialized countries (e.g.,
World Health Organization [WHO], United States Agency for
International Development, and the Department for
International Development) generally prefer to maintain
collaborative endeavors with sentinel centers for reasons
including adequate infrastructure, trained personnel, and
access to the ministry of health.
A high priority for future global consortiums of
epidemiology and biomedical research centers will be to
initiate or build upon existing systems in sentinel hospitals in
developing countries for the international monitoring and
reporting of antimicrobial susceptibility data. Two systems
that offer a foundation of international linkages are CDC’s
International Nosocomial Surveillance Program for Emerg-
ing Antimicrobial Resistance and the WHO Antimicrobial
Resistance Monitoring Program. The international and
national objectives of these programs depend on conducting
proper, quality-controlled, antimicrobial susceptibility test-
ing and promoting the use of resistance data to guide
antimicrobial therapy. These results, when integrated with
clinical and epidemiologic data on opportunistic and hospital
infections, may lead to substantial improvement in patient
outcomes.
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